suramin has been researched along with Vascular Diseases in 2 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin was given at 10 mg/kg once per week for two weeks." | 1.38 | Suramin alleviates glomerular injury and inflammation in the remnant kidney. ( Bayliss, G; Gong, R; He, S; Liu, N; Tolbert, E; Zhuang, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, N | 1 |
| He, S | 1 |
| Tolbert, E | 1 |
| Gong, R | 1 |
| Bayliss, G | 1 |
| Zhuang, S | 1 |
| Asghar, SS | 1 |
| Dingemans, KP | 1 |
| Kammeijer, A | 1 |
| Faber, WR | 1 |
| Abdel Mawla, MY | 1 |
2 other studies available for suramin and Vascular Diseases
| Article | Year |
|---|---|
Suramin alleviates glomerular injury and inflammation in the remnant kidney.
Topics: Ablation Techniques; Animals; Chemokine CCL2; Chemokine CCL5; ErbB Receptors; Gene Expression Regula | 2012 |
Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors.
Topics: Animals; Arthus Reaction; Blood Vessels; Chlorpromazine; Complement Activation; Complement C3; Compl | 1986 |